The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.
May 6th 2024
Study participants’ overall satisfaction with a mandatory nationwide adalimumab transition in New Zealand varied but was generally low.
Low Risk of Safety, Efficacy Concerns After Switching to a Biosimilar
March 6th 2018In an effort to evaluate whether switching from a reference biologic to a biosimilar could lead to altered clinical outcome, a research team, led by Hillel Cohen, PhD, conducted a systematic literature review of all available switching studies.
Read More